A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

NCT01689532 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

DRUG: Sirukumab 100 mg
DRUG: Sirukumab 50 mg
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.

Collaborators

[object Object]